el-Mangoush M, Singh N K
Al-Arab Medical University, Benghazi, Libya.
J Assoc Physicians India. 1992 Jul;40(7):452-4.
The efficacy of low-dose cytarabine given as 10 mg sub-cutaneously 12 hourly for 2 weeks and repeated at 2 to 3 weekly intervals was evaluated prospectively in 15 consecutive patients of myelodysplastic syndrome over a 3 year period. Response to therapy was assessed clinically and by haematological parameters including bone marrow examination. No patient achieved complete remission. Three patients responded partially. Four patients transformed into acute myelogenous leukaemia. Overall, the results of therapy were disappointing as all the 15 patients died within 6 months of diagnosis.
在3年期间，对15例连续性骨髓增生异常综合征患者前瞻性评估了小剂量阿糖胞苷的疗效，给药方式为每12小时皮下注射10毫克，持续2周，并以2至3周的间隔重复给药。通过临床评估以及包括骨髓检查在内的血液学参数评估治疗反应。没有患者实现完全缓解。3例患者部分缓解。4例患者转化为急性髓系白血病。总体而言，治疗结果令人失望，因为所有15例患者均在诊断后6个月内死亡。
